How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

75,669 results for

Cancer Prevention

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Guideline for the Prevention of Oral and Oro-pharyngeal Mucositis in Children Receiving Treatment for Cancer or Undergoing Hematopoietic Stem Cell Transplantation

Guideline for the Prevention of Oral and Oro-pharyngeal Mucositis in Children Receiving Treatment for Cancer or Undergoing Hematopoietic Stem Cell Transplantation Guideline for the Prevention of Oral and Oro-pharyngeal Mucositis in Children Receiving Treatment for Cancer or Undergoing Hematopoietic Stem Cell Transplantation Paul Gibson, MD Pediatric Oncologist Children’s Hospital, London Health Sciences Centre On Behalf of: The POGO Mucositis Prevention Panel Preaching to the Choir Oral (...) Mucositis is Important in Pediatric Cancer/HSCT • Pain • Inability to eat and drink • Hydration, TPN • Provides a portal of entry for bacteria • Dose limiting toxicity • QoL • Economic burden In 2014, POGO Supportive Care Panel recognized the need for a mucositis prevention CPG Approach • Multidisciplinary panel including Oncologists, Nursing, Pharmacist and Dentist • >130 RCTs mucositis prevention in adult and pediatric cancer • Interventions effective in adult populations likely to have a similar

2015 SickKids Supportive Care Guidelines

122. Overview of systematic reviews of non-pharmacological interventions for preventing and treating chemotherapy-induced peripheral neuropathy in cancer patients

Overview of systematic reviews of non-pharmacological interventions for preventing and treating chemotherapy-induced peripheral neuropathy in cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

123. A systematic review and meta-analysis of the efficacy of rectal washout in preventing local recurrence after anterior resection for rectal cancer

A systematic review and meta-analysis of the efficacy of rectal washout in preventing local recurrence after anterior resection for rectal cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

124. Effectiveness of various invitation methods to a colonoscopy in the early detection and prevention of colorectal cancer

Effectiveness of various invitation methods to a colonoscopy in the early detection and prevention of colorectal cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

125. Systematic review of aspirin in the prevention of hereditary and sporadic colorectal adenoma and cancer

Systematic review of aspirin in the prevention of hereditary and sporadic colorectal adenoma and cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

126. Direct oral anticoagulant (DOAC) versus placebo for the prevention of thrombosis in ambulatory patients with cancer at increased risk: a systematic review and meta-analysis

Direct oral anticoagulant (DOAC) versus placebo for the prevention of thrombosis in ambulatory patients with cancer at increased risk: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

127. The effect of probiotics for the prevention or treatment of cancer therapy (chemotherapy or radiotherapy) -induced oral mucositis: a systematic review and meta-analysis

The effect of probiotics for the prevention or treatment of cancer therapy (chemotherapy or radiotherapy) -induced oral mucositis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

128. The comparative efficacy and safety of novel oral anticoagulants, warfarin and low molecular weight heparin in patients with cancer to prevent venous thromboembolism: a network meta-analysis

The comparative efficacy and safety of novel oral anticoagulants, warfarin and low molecular weight heparin in patients with cancer to prevent venous thromboembolism: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

129. The effectiveness of mHealth interventions for cervical cancer prevention among women in high income countries

The effectiveness of mHealth interventions for cervical cancer prevention among women in high income countries Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

130. Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients

Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

131. Prevention of breast and cervical cancer in refugees and asylum seekers: a systematic review and meta-analysis

Prevention of breast and cervical cancer in refugees and asylum seekers: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

132. Colonoscopic surveillance for preventing colorectal cancer in adults with ulcerative colitis, Crohn's disease or adenomas

Colonoscopic surveillance for preventing colorectal cancer in adults with ulcerative colitis, Crohn's disease or adenomas Colorectal cancer pre Colorectal cancer prev vention: ention: colonoscopic surv colonoscopic surveillance in adults with eillance in adults with ulcer ulcerativ ative colitis, Crohn e colitis, Crohn's disease or 's disease or adenomas adenomas Clinical guideline Published: 23 March 2011 nice.org.uk/guidance/cg118 © NICE 2018. All rights reserved. Subject to Notice of rights (...) cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 23Contents Contents Introduction 4 Patient-centred care 6 1 Guidance 7 1.1 List of all recommendations 7 2 Notes on the scope of the guidance 12 3 Implementation 13 4 Research recommendations 14 4.1 Surveillance programmes for people at increased risk

2011 National Institute for Health and Clinical Excellence - Clinical Guidelines

133. Skin cancer prevention

Skin cancer prevention Skin cancer pre Skin cancer prev vention ention Public health guideline Published: 26 January 2011 nice.org.uk/guidance/ph32 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Skin cancer prevention (PH32) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 64Contents Contents Overview 5 Who is it for? 5 Introduction 6 1 Recommendations 7 Introduction 7 What the guidance covers 7 What

2011 National Institute for Health and Clinical Excellence - Clinical Guidelines

134. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. (PubMed)

Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Substantial preclinical data suggest estrogen's carcinogenic role in prostate cancer development; however, epidemiological evidence based on circulating estrogen levels is largely null. Compared with circulating estrogen, the intraprostatic estrogen milieu may play a more important role in prostate carcinogenesis. Using a nested (...) case-control design in the Prostate Cancer Prevention Trial (PCPT), we examined associations of genetic variants of genes that are involved in estrogen synthesis, metabolism and function with prostate cancer risk. A total of 25 potentially functional single nucleotide polymorphisms (SNPs) in 13 genes (PGR, ESR1, ESR2, CYP17A1, HSD17B1, CYP19A1, CYP1A1, CYP1B1, COMT, UGT1A6, UGT1A10, UGT2B7, UGT2B15) were examined in whites only. Controls (n = 1380) were frequency matched to cases on age, PCPT

Full Text available with Trip Pro

2018 Carcinogenesis

135. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer. (PubMed)

A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer. Explaining genetic predisposition in Hereditary Breast and Ovarian Cancer (HBOC) families without BRCA mutations is crucial. Germline PALB2 inactivating mutations were associated with an increased risk of HBOC due to its role in DNA repair through cooperation with BRCA proteins. The prevalence and penetrance of PALB2 mutations in Spanish HBOC patients remains unexplained. PALB2 (...) . Although PALB2 truncating mutations are rarely identified, segregation analysis and early onset cancer suggest a significant contribution to HBOC susceptibility in the Spanish population. PALB2 screening may improve genetic counselling through prevention measures, pedigree management and PARP inhibitor therapy selection.Copyright © 2018 Elsevier Ltd. All rights reserved.

2018 Breast

136. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. (PubMed)

Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. Investigators have used administrative claims to better understand cancer outcomes when a research question cannot feasibly be examined within a study. The Prostate Cancer Prevention Trial (PCPT) showed that seven years of finasteride reduced prostate cancer (PC) risk by 25% in men age 55 years or older. However, it was unclear whether the observed reduction in PC

2018 Journal of the National Cancer Institute

137. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. (PubMed)

A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. Identifying female carriers of BRCA1 and BRCA2 mutations is imperative for prevention of ovarian cancer and breast cancer. There are five major histologic subtypes of ovarian cancer and high grade serous cancer (the most common) is reported in 75-100% of BRCA1 and BRCA2 mutation carriers. We examined histology-based referral (...) to the Hereditary Cancer Program following an educational prevention campaign recommending BRCA1 and BRCA2 mutation screening for all high-grade serous cancer patients.We conducted a population-based retrospective study in the province of British Columbia, Canada that included all patients visiting the Hereditary Cancer Program for genetic counselling for BRCA1 and BRCA2 mutation between 2001 and 2014. We examined the difference in rates of BRCA1 and BRCA2 testing between serous cancer patients and endometrioid

Full Text available with Trip Pro

2018 BMC Cancer

138. Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study. (PubMed)

Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study.

2016 Lancet

139. Improvement of cancer control in mainland China: epidemiological profiles during the 2004-10 National Cancer Prevention and Control Program. (PubMed)

Improvement of cancer control in mainland China: epidemiological profiles during the 2004-10 National Cancer Prevention and Control Program.

2016 Lancet

140. To accelerate cancer prevention in Europe: Challenges for cancer registries. (PubMed)

To accelerate cancer prevention in Europe: Challenges for cancer registries. The availability of population-based cancer registry (CR) data is paramount in the development of modern oncology. Major contributions consisted in accurately measuring cancer burden (incidence, survival and prevalence, beside mortality), identifying and quantifying risk factors (case control and cohort studies that, in the last two decades, included gene variant assessment) and evaluating outcomes of treatments (...) and preventive interventions, including mass screening. Cancer registration coverage of European populations progressed slowly since 1940 and is now almost 50%. Areas lacking high-quality national population-based cancer registration still exist within large countries such as France, Italy, Romania and Spain, Germany and Poland having national plans and legislation to reach complete coverage. Depending on programme ownership, history and institutional organisation, European CRs showed huge variations

2018 European Journal of Cancer

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>